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Non-Hodgkin lymphoma (NHL) is the third most common childhood malignancy with an overall incidence of 10.5 per million.1 Its 
incidence is higher in the Middle East as a result of an 
increased incidence of endemic Burkitt lymphoma. It 
is usually restricted to lymphoid tissue such as lymph 
modes, Peyer patches, and the spleen.1 Primary hepatic 
NHL is very rare in the pediatric age range. It may be 
asymptomatic and discovered accidentally or present 
with non-specific symptoms like abdominal discomfort 
and/or pain with some constitutional manifestation.2 
We report a rare case of primary hepatic NHL present-
ing as acute hepatitis in a child aged 2.5 years who re-
sponded to chemotherapy.
CASE
A 2.5-year-old boy was admitted to our hospital with 
jaundice, a disturbed level of consciousness and irrita-
bility. On examination he had jaundice and was drowsy, 
with a coma score of 12/15 (Glascow coma score), 
edema of the lower limbs with no bleeding tendency or 
lymphadenopathy. There was low-grade fever of 38ºC 
to 38.5ºC. Blood pressure was 100/70 mm Hg with 
good perfusion. Urine output was about 1.2 mL/kg/h. 
Abdominal examination found a generalized abdomi-
nal enlargement, hepatomegaly (liver span 14 cm), with 
a firm, smooth nontender surface, no splenomegaly, and 
with moderate ascites. 
Laboratory investigations were as follows: random 
blood glucose was 80 mg/dL, blood gases and electro-
lytes were normal (pH of 7.36, sodium of 135 mEq/L, 
potassium of 3.5 mEq/L), creatinine of 1.7 mg/dL, 
erythrocyte sedimentation rate of 3/7 mm/h (hours 
1 and 2), serum albumin of 3.3 gm/dL, total serum 
bilirubin of 8.6 mg/dL (direct bilirubin of 6.5 mg/dL), 
AST of 942 U/L, and ALT of 1018 U/L. The complete 
blood count was as follows: total leukocytic count 7100 
mm3 (lymphocytes of 2000 mm3, granulocytes of 4300 
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mm3), platelets of 440 000/cm3. Prothrombin time was 
18.5/12.5 seconds, prothrombin activity was 44%, INR 
was 1.9. The Paul Bunnel test for Ebstein-Barr virus in-
fection was negative and bone marrow examination was 
normal. He was provisionally misdiagnosed as having 
hepatic encephalopathy, post-hepatitis A viral infec-
tion, but serologic analysis revealed that hepatitis A vi-
rus IgM (HAV IgM) was negative. Hepatitis B and C 
viruses markers were also negative.
The patient was treated for encephalopathy by IV 
fluids and branched amino acids, IV mannitol, IV flu-
mazenil, lactulose oral and enemas for four days with 
improvement in the level of consciousness, but the ab-
dominal enlargement increased so an abdominal ultra-
sound was done (Figure 1). The abdominal ultrasound 
revealed a hypo-echoic lesion 6×4 cm at the left lobe 
of the liver with similar smaller multiple lesions at the 
right lobe suggestive of abscess or infarctions, with 
moderate ascites with internal echoes suggestive of 
infection. Aspirated ascitic fluid was thick and turbid, 
with protein 370 mg/dL, glucose 23 mg/dL, and WBC 
of 10 000 (80% polymorphs and 20% lymphocytes). 
Therefore, septic peritonitis was suspected, and the 
Figure 1. Two masses in the right and left lobe of the liver.
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patient received cefotaxime and IV metronidazole. A 
drain was introduced, which drained about 500 mL of 
ascitic fluid per day. A triphasic CT scan of the chest and 
abdomen revealed marked enlargement of the liver with 
diffuse hypo-dense areas in the right and left lobes, main-
ly at the porta-hepatis, with moderate ascites (Figure 2). 
An ultrasound-guided liver biopsy revealed diffuse infil-
tration by tumor tissue (Figure 3), which was formed of 
densely arranged medium sized neoplastic rounded cells, 
uniform in size and shape with slightly indented nuclei 
and a small rim of cytoplasm (malignant round cells in-
filtration, which is highly consistent with non-Hodgkin 
lymphoma, Burkitt type). The same finding was con-
firmed in the peritoneal aspirate (Figure 4). We per-
formed immunohistochemical staining for CD3, CD10 
and CD20, applying monoclonal antibodies from Dako 
(Denmark) and Envision detection system. Diamino 
Benzedin (DAB) was applied as chromogen. CD20 and 
CD10 were diffusely positive, and CD3 was negative. A 
positive CD10 and CD20 supported the diagnosis of 
Burkitt lymphoma. On these bases, a diagnosis of Non-
Hodgkin lymphoma (Burkitt type) was made.
The patient received chemotherapy (COMP proto-
col: IV cyclophosphamide, IV vincristine, IV and intra-
thecal methotrexate, and oral prednisone). We applied 
half of the dose due to the elevated bilirubin and liver 
enzymes. Then the full dose was given when these el-
evations were normalized and he achieved remission.
DISCUSSION
Non-Hodgkin lymphoma (NHL) accounts for 6% to 
7% of malignant diseases in childhood in Europe and 
the United States. It represents about 45% of all lym-
phomas in children.1 Lymphomas are a diverse collec-
tion of different diseases with varying histologies and 
clinical presentations. Although secondary involvement 
of the liver is commonly found in advanced lymphoma, 
primary hepatic NHL is a rare and poorly character-
ized disease.2 
Lymphoma that presents with disease confined to 
the liver appears to be extremely rare. A retrospective 
cancer registry study published 30 years ago identified 
only 1467 cases of primary extranodal disease in a da-
tabase of 12 447 white patients with lymphoma (12%). 
Only 6 of the extranodal lymphomas (0.05% of the to-
tal) were said to arise from the liver or biliary system.3 
Similarly, a prospective population-based Dutch survey 
identified 580 newly diagnosed cases of lymphoma from 
1981 through 1986, none of which were considered to 
be primarily hepatic.4 Fewer than 150 cases have been 
reported in the worldwide literature.2 
Primary hepatic NHL occurs over a wide age range 
Figure 2. marked enlargement of the liver with diffuse hypo-
dense areas (CT abdomen).
Figure 3. Hematoxylin-eosin stain of the liver biopsy: atypical 
lymphoid cells with frequent apoptotic bodies infiltrating the liver 
tissue. 
Figure 4. Hematoxylin-eosin stain of peritoneal aspirate: atypical 
lymphoid cells in the peritoneal aspirate.
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but is most commonly a disease of middle age. It occurs 
twice as frequently and at a younger age in men than 
in women.5 It is very rare in pediatrics, having been re-
ported only once in a 9-year-old child.6 Presentation is 
usually nonspecific, with the most frequently reported 
symptom being abdominal discomfort or right upper 
quadrant pain. Constitutional symptoms such as fever, 
anorexia, and weight loss are common. As many as 10% 
of patients will be asymptomatic; primary hepatic NHL 
will only be discovered after an evaluation for incidental 
hepatic abnormalities. The most common physical find-
ing is hepatomegaly, which is present in 62% to 82% of 
cases. Jaundice is usually a late manifestation of disease 
progression and can be caused by periportal adenopa-
thy or it can be related to underlying cirrhosis.5 
Case series that have addressed the rare presenta-
tion of rapidly progressive hepatic failure suggest that it 
is usually associated with widespread systemic disease. 
Fulminant liver failure from lymphoma is characterized 
by jaundice, encephalopathy, coagulopathy, and lactic 
acidosis. It is associated with an extremely poor out-
come, with an average survival of only 10.7 days from 
diagnosis. In many cases, the correct diagnosis is not 
made until autopsy.7
Blood counts are usually normal in the early stages 
of primary hepatic NHL. As the disease progresses, 
hypersplenism and bone marrow involvement lead to 
more frequent abnormalities. Blood chemistry evalu-
ations demonstrate increases in liver function tests in 
75% to 85% of cases. As a well-established marker in 
lymphoid malignancy, the lactate dehydrogenase level 
is increased in 85% of cases whereas measurements of 
α-fetoprotein and carcinoembryonic antigen are usually 
normal.5 There is no identifiable laboratory pattern that 
is specific for hepatic lymphoma.2
 Lymphoma can involve the liver as one or more dis-
crete masses. In a series of 31 patients with primary he-
patic NHL, a multinodular presentation was reported 
in the majority of patients (55%), followed by a solitary 
hepatic nodule in 39% and diffuse disease in 6%.8
 Computed tomography (CT) usually demonstrates 
the presence of homogeneous low-attenuation masses 
that may have a thin enhancing rim after contrast ma-
terial administration, and larger masses can have areas 
of very low-density reflective of necrosis. Diffusely 
infiltrative disease can present as hepatomegaly with 
little alteration in parenchymal density or architectural 
distortion. Ultrasonography usually demonstrates the 
presence of hypoechoic homogenous masses that cor-
relate well with findings on CT imaging.9
More than half of all hepatic lymphomas fall within 
the category of diffuse large-cell lymphoma.10 Primary 
Burkitt lymphoma of the liver has been reported, some-
times in association with human immunodeficiency virus 
(HIV) or hepatitis C virus (HCV).11 Mucosa-associated 
lymphoid tissue (MALT)-type lymphoma is the most 
common low-grade histology, although follicular and lym-
phoplasmacytic lymphomas have also been described. 
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